1
|
Siegel HJ, Sessions W, Casillas MA Jr, et
al: Synovial sarcoma: clinicopathologic features, treatment, and
prognosis. Orthopedics. 30:1020–1025. 2007.PubMed/NCBI
|
2
|
Liu CY, Yen CC, Chen WM, et al: Soft
tissue sarcoma of extremities: the prognostic significance of
adequate surgical margins in primary operation and reoperation
after recurrence. Ann Surg Oncol. 17:2102–2111. 2010. View Article : Google Scholar : PubMed/NCBI
|
3
|
Stojadinovic A, Leung DH, Hoos A, Jaques
DP, Lewis JJ and Brennan MF: Analysis of the prognostic
significance of microscopic margins in 2,084 localized primary
adult soft tissue sarcomas. Ann Surg. 235:424–434. 2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Morrison BA: Soft tissue sarcomas of the
extremities. Proc (Bayl Univ Med Cent). 16:285–290. 2003.PubMed/NCBI
|
5
|
Kitagawa C, Saka H, Kajikawa S, Mori K,
Oki M and Suzuki R: Phase I and pharmacologic study of weekly
amrubicin in patients with refractory or relapsed lung cancer:
Central Japan Lung Study Group (CJLSG) 0601 trial. Cancer Chemother
Pharmacol. 69:1379–1385. 2012. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zeren H, Moran CA, Suster S, Fishback NF
and Koss MN: Primary pulmonary sarcomas with features of monophasic
synovial sarcoma: A clinicopathological, immunohistochemical and
ultrastructural study of 25 cases. Hum Pathol. 26:474–480. 1995.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Hartel PH, Fanburg-Smith JC, Frazier AA,
et al: Primary pulmonary and mediastinal synovial sarcoma: A
clinicopathologic study of 60 cases and comparison with five prior
series. Mod Pathol. 20:760–769. 2007. View Article : Google Scholar : PubMed/NCBI
|
8
|
Watzka SB, Setinek U, Prosch H and Müller
MR: Primary synovial sarcoma of the lung as an incidental finding.
Interact Cardiovasc Thorac Surg. 9:1026–1028. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Frazier AA, Franks TJ, Pugatch RD and
Galvin JR: From the archives of the AFIP: Pleuropulmonary synovial
sarcoma. Radiographics. 26:923–940. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
dos Santos NR, de Bruijn DR and van Kessel
AG: Molecular mechanisms underlying human synovial sarcoma
development. Genes Chromosomes Cancer. 30:1–14. 2001. View Article : Google Scholar : PubMed/NCBI
|
11
|
Miura Y, Keira Y, Ogino J, et al:
Detection of specific genetic abnormalities by fluorescence in situ
hybridization in soft tissue tumors. Pathol Int. 62:16–27. 2012.
View Article : Google Scholar : PubMed/NCBI
|
12
|
Cuffe S, Moua T, Summerfield R, Roberts H,
Jett J and Shepherd FA: Characteristics and outcomes of small cell
lung cancer patients diagnosed during two lung cancer computed
tomographic screening programs in heavy smokers. J Thorac Oncol.
6:818–822. 2011. View Article : Google Scholar : PubMed/NCBI
|
13
|
Bacha EA, Wright CD, Grillo HC, et al:
Surgical treatment of primary pulmonary sarcomas. Eur J
Cardiothorac Surg. 15:456–460. 1999. View Article : Google Scholar : PubMed/NCBI
|
14
|
Shah CM: Amrubicin: A synthetic
anthracyclin analogue in the treatment of extensive stage small
cell lung cancer. Recent Pat Anticancer Drug Discov. 4:241–245.
2009. View Article : Google Scholar : PubMed/NCBI
|
15
|
Walczak BE and Irwin RB: Sarcoma
chemotherapy. J Am Acad Orthop Surg. 21:480–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
16
|
Weiss RB: The anthracyclines: Will we ever
find a better doxorubicin? Semin Oncol. 19:670–686. 1992.PubMed/NCBI
|
17
|
Suzuki T, Minamide S, Iwasaki T, Yamamoto
H and Kanda H: Cardiotoxicity of a new anthracycline derivative
(SM-5887) following intravenous administration to rabbits:
Comparative study with doxorubicin. Invest New Drugs. 15:219–225.
1997. View Article : Google Scholar : PubMed/NCBI
|
18
|
Noda T, Watanabe T, Kohda A, Hosokawa S
and Suzuki T: Chronic effects of a novel synthetic anthracycline
derivative (SM-5887) on normal heart and doxorubicin-induced
cardiomyopathy in beagle dogs. Invest New Drugs. 16:121–128. 1998.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Fulbright JM, Huh W, Anderson P and
Chandra J: Can anthracycline therapy for pediatric malignancies be
less cardiotoxic? Curr Oncol Rep. 12:411–419. 2010. View Article : Google Scholar : PubMed/NCBI
|
20
|
Ogawara D, Fukuda M, Nakamura Y and Kohno
S: Efficacy and safety of amrubicin hydrochloride for treatment of
relapsed small cell lung cancer. Cancer Manag Res. 2:191–195.
2010.PubMed/NCBI
|
21
|
Onoda S, Masuda N, Seto T, et al: Thoracic
Oncology Research Group Study 0301: Phase II trial of amrubicin for
treatment of refractory or relapsed small-cell lung cancer:
Thoracic Oncology Research Group Study 0301. J Clin Oncol.
24:5448–5453. 2006. View Article : Google Scholar : PubMed/NCBI
|
22
|
Harada T, Oizumi S, Ito K, et al: Hokkaido
Lung Cancer Clinical Study Group: A phase II study of amrubicin as
a third-line or fourth-line chemotherapy for patients with
non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study
Group Trial (HOT) 0901. Oncologist. 18:439–445. 2013. View Article : Google Scholar : PubMed/NCBI
|